Overview
This observational study aims to evaluate the outcomes of patients with early-stage epithelial ovarian cancer who are treated with minimally invasive surgery (such as laparoscopic or robotic surgery). Specifically, the study will look at:
- Post-Surgery Complications
- What is the rate of complications within 30 days after surgery?
- How often do patients require readmission to the hospital, re-operation, or conversion to open surgery?
- Cancer Outcomes
- What is the rate of cancer upstaging (when the cancer spreads to a more advanced stage during surgery for example because of an intra-operative ovarian cyst rupture)?
- What are the overall survival and disease-free survival rates for patients treated with minimally invasive surgery?
Researchers will compare two groups of patients:
Group 1: Patients with early-stage ovarian cancer treated with minimally invasive surgery.
Group 2: Patients with early-stage ovarian cancer treated with open surgery. The goal is to see if there are any differences in post-surgery complications, recovery, and cancer outcomes between the two groups.
Fertility-Sparing Treatment:
The study will also compare patients who are undergoing fertility-sparing treatments for early-stage ovarian cancer. Two subgroups will be looked at:
- Patients receiving fertility-sparing surgery through a minimally invasive procedure.
- Patients receiving fertility-sparing surgery through an open surgery. The same outcomes (complications, survival, etc.) will be assessed and compared between these two groups as well.
Eligibility
Inclusion Criteria:
- Patients with apparent early-stage epithelial ovarian cancer at preoperative evaluation
- Patients who underwent surgery between January 2014 and December 2023
- Patients who underwent open or minimally invasive surgical staging (Laparoscopic or Robotic-assisted approach) or restaging procedure
- Patients with final pathology report of Epithelial Ovarian Cancer
Exclusion Criteria:
- Patients who have not performed a complete surgical staging
- Patients who underwent neoadjuvant chemotherapy
- Patients with invasive synchronous tumor
- Patients with no informed consent
- Patients with ASA class score of 4 or 5